Radiopharmaceutical developer Navidea Biopharmaceuticals and the University of Alabama at Birmingham (UAB) have received a $225,000 grant from the U.S. National Institutes of Health (NIH) to assess the use of the company's gallium 68 (Ga-68) tilmanocept radiopharmaceutical in PET imaging of atherosclerotic plaques.
The award was provided by the NIH's National Heart, Lung, and Blood Institute under its Small Business Technology Transfer Phase 1 grant program. The studies, which will be performed in partnership with co-principal investigator Suzanne Lapi, PhD, at the UAB, will compare the performance of Ga-68 tilmanocept PET with FDG-PET for imaging atherosclerotic plaques in a relevant mice model, the company said.
